RB1 and neoplasm: As a new class of targeted small molecule drugs, ribociclib can selectively block Rb protein phosphorylation process to block tumor proliferation, and thus play an anti-tumor role.[13,14] The MONALEESA series of clinical studies on Ribociclib included MONALEESA-2, MONALEESA-3 and MONALEESA-7.